Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.

Attachment: Financial summary

(In thousands of

US dollars,

except share

and per share data)

Three months ended Year ended

CONSOLIDATED RESULTS December 31, December 31,

Unaudited 2007 2006 2007 2006

-------------------------------------------------------------------------

-------------------------------------------------------------------------

$ $ $ $

Revenues

Sales and royalties 6,435 6,800 28,825 25,123

License fees 3,705 5,137 12,843 13,652

Other 100 - 400 24

-------------------------------------------------------------------------

10,240 11,937 42,068 38,799

-------------------------------------------------------------------------

Operating expenses

Cost of sales, excluding

depreciation and

amortization 3,255 3,556 12,930 11,270

Selling, general and

administrative 5,146 4,159 20,403 16,478

R&D costs 13,574 7,926 39,248 27,422

R&D tax credits and grants (1,941) (1,442) (2,060) (1,564)

Depreciation and

amortization 1,135
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ) ... Global Survey on Flow Cytometry Adoption Trends" ... goal of this research is to analyze the ... information the survey seeks to collect include factors ... used applications for flow cytometers, respondents, most preferred ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... (PBS-Bio) decodes the workings of drugs made by two private firms ... the American Association for Cancer Research. The conference runs April ... The presentations will be given on April 5. In ... a Belgian firm, affects two genes MCL1 and MYC. ...
... Ill. With the first observation of thermoelectric effects ... graphene transistors have a nanoscale cooling effect that reduces ... professor William King and electrical and computer engineering professor ... the April 3 advance online edition of the journal ...
... cannot be focused to spot sizes smaller than half ... approach to beat this diffraction limit is based on ... radiofrequency counterparts. They have the ability to concentrate (focus) ... orders of magnitude smaller than what conventional lenses can ...
Cached Biology Technology:TGen and PBS-Bio presents 2 abstracts at AACR conference 2Self-cooling observed in graphene electronics 2Transmission lines for nanofocusing of infrared light 2Transmission lines for nanofocusing of infrared light 3
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... NPL worked with Ecobrands Ltd to characterise their Zap-It! ... piezoelectric material to relieve the pain and itching caused by ... is a pocket-sized product, marketed by Ecobrands, that is based ... ignition source in electronic lighters. It is a medical device, ...
... NEW BRUNSWICK, NJ: - Atmospheric oxygen really took off ... Great Oxygenation Event. At this key juncture of our planet,s ... poison that was produced by photosynthesizing cyanobacteria or they went ... that sustains much of modern life had such a distasteful ...
... methicillin-resistant Staphylococcus aureus (MRSA) bacteria that humans contract ... resistance to antibiotics once it was picked up by farm ... mBio on Tuesday, February 21, illustrate a very close ... human infections. MRSA is the well-known cause of ...
Cached Biology News:Zapping mosquito bites 2The origin of photosynthesis revealed 2MRSA in livestock acquired drug resistance on the farm, now infects humans 2